These findings suggest that GLP-1 receptor agonists may be a viable therapeutic option for patients with coexisting T2DM, severe obesity, and stable CML, warranting further investigation in broader populations. This evidence concerns the gene GLP1R and chronic myelogenous leukemia, BCR-ABL1 positive.